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Cancer is a group of diseases that affects 1.6 million and kills nearly 600,000 Americans 
each year. The National Cancer Institute defines it as “diseases in which abnormal cells divide 
without control and can invade nearby tissues” and it is often treated with one or more of the 
following: chemotherapy, radiation, surgery.  The expense for these treatments is expected to rise 
to $156 billion by 2020. Localized delivery can improve effectiveness and cancer survival rates, 
decrease the cost of treatment, and decrease the side effects of chemotherapy. This paper addresses 
models for this localized delivery through nanoemulsions. Nanoemulsions are a spherical layer of 
a hydrophobic substance holding and surrounded by hydrophilic substances or a spherical layer of 
a hydrophilic substance surrounded by and holding hydrophobic substances with a diameter less 
than one micrometer. Nanoemulsions are in development for cancer treatment due to their 
thermodynamic stability, which improves shelf-life.  
While nanoemulsions on their own do not provide specific targeting, two potential options 
for targeted and local delivery are addressed here. This paper explores the effect of AS1411, an 
aptamer which can target some cancer cells, on nanoemulsions for chemotherapy delivery. 
AS1411 binds to nucleolin, which is overexpressed in many cancer cells and appears on their 
surface, allowing AS1411 to target them. AS1411 also has the ability to inhibit cancer cell 
functions and kill cancer cells selectively. When taken into healthy cells, AS1411 is removed 
through exocytosis or efflux instead of damaging them. Using AS1411 on nanoemulsions should 
cause the cancerous cells to actively absorb the nanodroplets while limiting uptake by healthy 
cells.  
Ultrasound-induced vaporization is also explored as a way to cause nanoemulsions to 
release their payload into cancer cells. Vaporization of the nanoemulsion droplets weakens 
surrounding membranes and forces drugs out of nanoemulsions as microjets. This method can be 
used on many cancers, especially those near to the skin as there is less interference. One caveat is 
that ultrasound may not be safe for lung cancer treatments, as ultrasound cannot penetrate air in 
the lungs and the reflected waves may damage healthy lung tissue. These additions to systemic 





MDA-MB-231 breast cancer cells and on artificially grown tumors, called spheroids. This 
spheroid testing allows for a look into how these treatments may be affected by avascular tumors, 
which are more drug resistant than normal cancer.  
To test the effects of these treatment options, FITC-labeled or doxorubicin-loaded 
nanoemulsions were produced and applied on top of the cancerous cells. Doxorubicin was used 
due to its chemotherapeutic properties and its lack of interference with MTT assay readings. Some 
samples were created with AS1411 covalently bound to the outside while others were created with 
no payload or targeting to act as a control. After a period of incubation the nanoemulsions in some 
samples are ultrasonicated while others remain untouched as control. Following further incubation, 
the cells were harvested and assayed for analysis, using flow cytometry for FITC detection and an 
MTT assay for doxorubicin-induced cytotoxicity detection.  
The results of these tests showed that ultrasound improved cytotoxicity in doxorubicin-
treated spheroids but worsened FITC uptake. This reduced FITC uptake may be caused by holes 
in the cell membrane induced by ultrasound, allowing FITC to leak back out of the cells. AS1411, 
both with and without ultrasound, had an insignificant effect on cytotoxicity in this study. The lack 
of consistent improvement by AS1411 may be due to the use of cancerous cells exclusively in our 
spheroids, which result in all of the nanoemulsions releasing their payloads onto the cancer 
regardless of whether or not they bind to their nucleolin. Another theory is that the incubation 
times were too long, so the passive uptake of the nanoemulsions was able to overshadow to the 
active uptake stimulated by AS1411. The results of this research encourage further study into the 
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Spheroid = An artificially grown tumor in a nearly spherical shape. 
Nanoemulsion = A drop of oil in water or a drop of water in oil ranging between 20 and 200 nm.   
AS1411 = A chain of DNA that reads 5’-GGTGGTGGTGGTTGTGGTGGTGGTGG-3’. It has 
been shown to have both anti-cancer and cancer targeting properties.  







LIST OF FIGURES 
 
Figure 1: A photo of an MDA-MB-231 spheroid grown in this lab………………………………2 
Figure 2: MTT absorbance  vs. doxorubicin concentration and seeding cell density……………10 
Figure 3: 15k seeded spheroid after 5 days of growth and 50 µM doxorubicin (left) and a 15k 
seeded spheroid after 5 days of growth and no doxorubicin treatment (right) (spheroid plate, 
cropped)………………………………………………………………………………………….10 
Figure 4: Absorbance of MTT treated spheroids following doxorubicin treatments at different 
times……………………………………………………………………………………………...11 
Figure 5: Percent Viability of MDA-MB-231 Cells Following Doxorubicin Treatment………..13 
Figure 6: Weekly fluorescence test to determine nanoemulsion lifespan through treatment of flat 
cells……………………………………………………………………..…………………...…...13 
Figure 7: Percent Viability determined via plate reading for MTT treated (2 hour incubation) 
spheroids treated with doxorubicin nanoemulsions and ultrasound……………………………..15 
Figure 8: Average plate reading for MTT treated (2 hour incubation) spheroids treated with un-
sonicated doxorubicin nanoemulsions……………………………………………………….…..15 
Figure 9: The combined data from Figure 8 and 9. The normalized values of the absorbance from 
spheroids………………….………………………………………………………………….…..16 
Figure 10: Absorbance of MTT treated spheroids following doxorubicin treatment. Each 
emulsion sample contained 10µL of nanoemulsions, with the percentage indicating the amount 
that contained doxorubicin. Ultrasound occurred 30 minutes following nanoemulsion place.….17 
Figure 11: Absorbance of MTT treated spheroids following liquid doxorubicin treatment……..18 
Figure 12: Normalized values from Total Cell Association Flow Cytometry MACS Quantity 





Figure 13: A normalized graph showing the cells counted via Total Cell Association Flow 
Cytometry MACS Quantity Analyzer containing FITC or Cy5 immediately following ultrasound 
treatment of spheroids (1=158.5 cells)…………………………………………………………..19 
Figure 13: Absorbance of MTT in spheroids following nanoemulsion treatments. The number of 
blank nanoemulsions in each group is equal to the amount of nanoemulsions at that concentration 
of doxorubicin for drug emulsions………………………………………………..……………...20 





Cancer is a group of diseases in which body cells grow abnormally and damage other cells. 
It is a growing global concern and is now responsible for one in every six deaths, making it the 
second leading cause of death worldwide (WHO). The market for cancer treatment in the United 
States is growing (NCI) and new treatments are constantly in development. Traditional 
chemotherapy kills rapidly multiplying cells, which also results in damage to normal tissues, such 
as bone marrow, hair, and digestive tract tissues (ACS). To enhance the effectiveness of 
chemotherapy on cancerous cells and limit these side effects, targeted delivery is being researched. 
This paper addresses adaptations to nanoemulsion delivery to become a targeted therapy.  
Nanoemulsions are a type of nanoparticle where a layer of hydrophobic material surrounds 
a hydrophilic core or a hydrophilic material surrounds a hydrophobic core. These particles can be 
used as drug vehicles to protect and carry chemotherapies throughout a body. Nanoemulsions are 
also small enough (50-200 nm) to pass through leaky vasculature and accumulate in tumors, 
resulting in higher delivery to cancer cells (Zhou). Ultrasound can be applied to perfluorocarbon-
based nanoemulsions and can cause them to vaporize due to the low boiling point of the 
perfluorocarbon. This process can induce cavitation of the vaporized droplets, which can result in 
microstreaming and enhance drug delivery to nearby cells whose membranes were permeabilized 
by the ultrasound (Zhou). While vaporization and cavitation cannot target individual cell types, 
ultrasound can be focused to an area to specifically vaporize nanoemulsions there, resulting in 
localized delivery.  
AS1411 is an aptamer discovered by Bates et al. which binds to nucleolin. It is 26 
nucleotides long and reads 5’-GGTGGTGGTGGTTGTGGTGGTGGTGG. AS1411 is removed 
via efflux in normal cells, but in cancer cells is absorbed by micropinocytosis and increases in 
concentration (Bates). AS1411 also binds to nucleolin that appears on the membranes of cancer 
cells, allowing it to function as a targeting molecule (Luo et al.).  
Spheroids are artificially grown tumors. The use of spheroids in these experiments should 





performing in vivo experimentation (Ivascu). Ultrasound cavitation, due to the creation of 
microjets, should be able to deliver drugs further into spheroids compared to spheroids not treated 
with ultrasound. Concerns have been raised that this cavitation could break cells off the tumor and 
induce metastasis, but no tests have been performed yet to verify this concern. If this is also true 
in vivo, ultrasound should improve the speed at which drugs kill cancer cells and give the cancers 
less time to metastasize. While AS1411 is not anticipated to have an additional effect on spheroids 
compared to flat tissue, spheroids should provide a more accurate model of drug delivery for in 
vivo comparisons. A photo of one spheroid from this lab is presented below as Figure 1.  
 
 
Figure 1: A photo of an MDA-MB-231 spheroid grown in this lab 
This project explores how AS1411 and ultrasonication each affect the uptake of 
chemotherapeutic nanoemulsions into cancer cells in spheroid formations. The uptake of AS1411 
into tumors has been tested before using fluorescent compounds, PGG-PTX, which is a 
nanoparticle-forming chemotherapy drug, and spheroids (Luo, et al.). The use of nanoemulsions 
to improve drug delivery to spheroids has also been tested, such as in the treatment of human 
mammary cancer cells with photodynamic therapy (Muehlmann, et al.). This project offers greater 





therapy and testing the combined treatment against both controls and the two augmentations alone. 
This is improved by the use of spheroids to simulate the three-dimensional tissue growth of tumors 







INSTRUMENTATION AND EQUIPMENT 
 
Spheroid Production: 
Spheroids were produced using MDA-MB-231 human breast carcinoma cells. Additional 
materials used were Trypsin-EDTA 0.05% (1 mL Trypsin-EDTA 0.25%: 4 mL PBS), sterile PBS, 
deionized (DI) water, Dulbecco’s Modified Eagle Medium (DMEM) cell culture media, dry agar 
powder, autoclave-safe 250 mL flasks, an autoclave, a microwave, a sterile hood, 24-well and 96-
well plates, 96-well Corning ultra-low attachment spheroid plates, a hemocytometer, a shaker with 
speed of at least 120 rpm, a centrifuge with speed of at least 1500 rpm, pipettes, and pipette tips.  
MTT Assay Protocol: 
To perform the MTT assay, the following materials were used: MTT solution, lysis buffer, 
Trypsin-EDTA 0.25%, a plate reader, pipettes, and pipette tips. 
Cell Splitting/Harvesting 
To split and harvest cells the following materials were used: 10/25 mL cell flasks, MDA-MB-231 
Cells, Trypsin-EDTA 0.25%, Sterile PBS, deionized (DI) Water, Dulbecco’s Modified Eagle 
Medium (DMEM) media, a sterile hood, formaldehyde, pipettes, and pipette tips. 
Nanoemulsion Production 
To produce nanoemulsions, the following materials were used: Cy5-AS1411 aptamer, AS1411-
thiol aptamer, Tris(2-carboxyethyl)phosphine (TCEP), sodium phosphate buffer, maleimide lipid, 










Spheroid Production (Agar Method) 
Prepare 1.25% Agar for coating non-tissue culture treated plates: 
An autoclave safe 250 mL bottle was pre-warmed in a 40 oC water bath. 90mL of deionized H2O 
(DI water) was heated in the 250 mL bottle to 80-90 oC using a hot plate. A cap was placed on the 
flask at this point to prevent evaporation. 1.25 g of dry agar was added to the bottle and stirred 
with a glass rod until the lumps disappeared. The total volume of the bottle was raised to 100mL 
by adding DI water while the solution was being heated. The final solution was stirred with a 
magnetic stir bar until thoroughly mixed. The agar solution, still loosely capped, was autoclaved 
for 15 minutes at 121 oC using slow exhaust. The bottle was removed from the autoclave and 
allowed to cool prior to the cap being tightened. The solution was stored at room temperature.  
  
Agar coating of non-tissue culture treated plates (sterile conditions): 
The agar was warmed to its melting point (approximately 70 oC) by microwaving it at 30 power 
for 3 minutes followed by 100% power for 30 seconds. 200 µL (for a 24-well plate) or 100 µL (for 
a 96-well plate) of the agarose was pipetted into each well of a plate. The agar was pipetted up and 
down a few times in the hot agar to avoid dripping. The pipetting was done with smooth movement 
around the well. The tip of the pipet was changed every 12 samples to avoid agar building up and 
blocking it. The plate was stored at room temperature under sterile condition. After a few hours, 
the plate was checked to see if the agar had fully solidified, so cells could be plated.  
 
Create spheroids (sterile conditions):  
Human cancer (MDA-MB-231) cells were detached from 80% confluency using 0.05% trypsin. 
The cells were counted and centrifuged at 1500 rpm for 5 minutes in 4 oC. The amount of DMEM 
required for a final cell concentration of 100,000 cells/mL (24-well plate) or 60,000 cells/100 µL 
(96-well plate) was calculated using the cell count. The trypsin was aspirated and the cells were 





dilute the cell count than was needed to grow spheroids, some of the cells would be discarded. 1 
mL (24-well plate) or 100 µL (96-well plate) of cells and media were pipetted into each well of a 
round bottom ultra-low attachment plate (Corning Inc., Corning, NY, USA) or an agar treated flat 
bottom plate created in a previous step. The lid was placed on each plate and the plate was shaken 
at 120 rpm for 15 minutes to allow for aggregation. The cells were incubated for 37 oC for 3 to 7 
days.  
 
Spheroid treatment and disaggregation: 
After the spheroids were formed, various concentrations of treatments were applied to each well 
after being diluted to 1 mL per well (24-well plate) or 100 µL per well (96-well plate). A negative 
control (no treatment) and a positive control (all cells are killed) are applied to some wells for 
comparison. The spheroids are incubated for a set period of time. For 24-well plates, 1600 µL of 
media was removed from each well using a 200 µL pipet eight times and 600 µL of fresh trypsin 
was added to disaggregate the spheroids. For 96-well plates, 150 µL was removed from each well 
using a 200 µL pipet and 150 µL of fresh trypsin was added. The plates were then incubated for at 
least one more hour before being pipetted 3-5 times to disaggregate the spheroids. Cell viability 
was measured via MTT Assay.  
 
MTT Assay Protocol:  
0.1 mL (24-well plate) or 10 µL (96-well plate) of 5 mg/mL stock MTT solution was added to 
each well. Each well was incubated for 4 hours at 37 oC before 1 mL (24-well plate) or 100 µL 
(96-well plate) of lysis buffer was added to each well. The final solution was incubated overnight 
at 37 oC and read on a plate reader.  
  
Cell Splitting 
The source flask was examined under a microscope and the confluency of the cells was estimated. 
Cells were harvested when between 80%-90% confluency. 0.25% Trypsin and DMEM media were 
warmed to room temperature in a water bath. The source flask was held upside down and tiled so 
that the cap faced upwards. The cap was unscrewed and the media was aspirated from the corner 





avoided. The flask was washed with 3 mL PBS (10 mL flask) or 10 mL PBS (25 mL flask) before 
the PBS was aspirated using the stated technique. 3 mL (10mL flask) or 10 mL (25 mL flask) of 
0.25% Trypsin-EDTA was added to the flask. If the cells were to be used in spheroid production 
immediately, 0.05% Trypsin-EDTA was used instead, as per the spheroid protocols our lab uses. 
The cells were incubated at 37 oC for 1 minutes (0.25% trypsin) or 3 minutes (0.05% trypsin). The 
side of the flask was tapped vigorously to shake the cells loose and the flask was placed under a 
microscope. If some of the cells were not moving, the flask was tapped more. If, after two rounds 
of tapping, some cells still remained immobile, the flask was incubated for an additional minute 
before being tapped again. The trypsin was neutralized with 3 mL of DMEM for 10 mL flasks (the 
25 mL flasks did not require neutralization before transfer). A cell count was performed if required. 
X mL of cells were moved to the new flask and 10-X mL media was added to the new flask where 
X is 8/2(number of days until next splitting). The new flask was incubated at 37 oC, the remaining cells were 
aspirated and the old flask was disposed of in the biological materials waste bin.  
 
Cell Harvest Protocol 
This was performed at a set time following treatment. The media from the cell flask was aspirated 
and replaced with 500 µL of PBS. This PBS was then aspirated and replaced with 300 µL of 
trypsin. The flask was placed in an incubator for 1-2 minutes until the cells detached. The 
cell/trypsin mixture was pipetted into a 1.5 mL microcentrifuge tube with 300 µL media. The tube 
was centrifuged at 1500g for 5 minutes. A pipette was used to remove 400 µL of the supernatant, 
which was replaced with 200 µL of 4% formaldehyde. The sample was stored at 4oC until needed.  
 
Cell Fixing Protocol 
This was performed at a set time following treatment. The media was aspirated and 100 µL of PBS 
was added to each well of the 96-well plate.  200 µL of 4% formaldehyde was added to each 
sample before they were stored at 4 oC. 
 
Nanoemulsion Production  





A vacuum was applied to the maleimide lipid solution for 5 minutes. 200 µL deprotected AS1411 
was added to 800 µL maleimide lipid before the solution was stored at 4 oC overnight.  
  
For Fluorescent Aptamer Deprotection: 
132 µL of 100 mM sodium phosphate buffer, 15 µL 0.05 mM fluorescent aptamer (Cy5-AS1411) 
and 3 µL of 500 mM TCEP were added to a 1.5 mL centrifuge tube. 132 µL of 100 mM sodium 
phosphate buffer to a 1.5 mL centrifuge tube. The tube was gently mixed and incubated at room 
temperature for at least 1 hour. Exposing the fluorescent solutions to light was avoided.  
  
For Non-fluorescent Aptamer Deprotection: 
172 µL of 100 mM sodium phosphate buffer, 20 µL of 2 mM AS1411-thiol aptamer, and 8 µL of 
500 mM TCEP were added to a1.5 mL centrifuge tube. The tube was gently mixed and incubated 
at room temperature for at least 1 hour.  
 
Doxorubicin Nanoemulsion Production 
80 µL PFC and 5.8 µL of 17.24 mM doxorubicin hydrochloride solution was added to 200 µL of 
lipid solution (final concentration of doxorubicin was 500 µM in lipid) in a 15 mL tube. The tube 
was sonicated on ice at standard settings (60% amplitude, 5 cycles of 20 seconds on and 40 seconds 
off). The droplets were washed with centrifugation (2000g for 3 minutes at room temperature). 
The supernatant was removed and the pellet was re-suspended in 1 mL of PBS. The nanoemulsions 
were extruded through 200 nm membranes seven time and the final solution was stored in a 1.5 
mL centrifuge tube. 
  
Empty Nanoemulsion Production 
80 µL PFC and 5.8 µL PBS were added to 200 µL of lipid solution in a 15 mL centrifuge tube. 
The tube was sonicated on ice at standard settings (60% amplitude for 5 cycles of 20 seconds on, 
40 seconds off). The droplet emulsion was washed via centrifugation at 200g for 3 minutes in room 
temperature. The supernatant was removed and the pellet was resuspended in 1 mL PBS. The 
solution was extruded through 200 nm membranes 7 times. The final solution was stored in a 1.5 






 Fluorescent nanoemulsions were produced and applied to both single-layer and spheroid 
cancer cells. After 1 hour, half of the nanoemulsions were placed under ultrasound treatment for a 
fixed period of time. A one hour waiting period was chosen to allow for the nanoemulsions to 
potentially bind to receptors on the spheroid without too much passive uptake into the cells. Both 
ultrasound-treated and non-ultrasound treated emulsions were then be placed in incubation for an 
additional 2 days before results were obtained. Some samples were examined via flow cytometry. 
Other samples were sent through a plate reader for fluorescent reading. 
 
RESULTS AND DISCUSSION OF RESULTS 
1. Spheroid Production: 
Spheroids were produced with two methods to determine which was more consistent. The first 
method involved treating a normal 96-well plate with agar before attempting to grow cells. The 
second method was to use specially made spheroid plates with round, treated bottoms to prevent 
cell attachment. Spheroid size and shape were visually examined and photos were taken of both 
results. The method that produced uniformly sized spheroids with low aspect ratios was used in 
additional experiments. It was found that the spheroid plates performed better, as their round 
bottoms and surface treatments encouraged more consistent aggregation. As evidenced by Figure 
2 below, there is not a statistical difference between using 10k of cells and 15k of cells. 
Additionally, there is no statistical difference between using 5 and 50 µM of doxorubicin, though 
there is a difference between Control and every other concentration and 0.5 µM and every other 
concentration when testing the various sized spheroids. 
Figures 3 and 4 show the shape of spheroids and how high concentrations of doxorubicin 
disaggregate them. Figure 5 shows why other experiments were performed after 28 hours of 
treatment, as the standard deviation for MTT absorbance was consistently smaller with less time. 
The nanoemulsion data was not normal, so ANOVA could not be performed, but they do show 
that for liquid doxorubicin the control group and 5 µM liquid doxotubicin group there is no 
statistical difference in absorbance, but there is a difference between each of 50 µM and 25 µM 






Figure 1: MTT absorbance  vs. doxorubicin concentration and seeding cell density 
 
Figure 2: 15k seeded spheroid after 5 days of growth and 50µM doxorubicin (left) and a 15k seeded spheroid after 5 days of 
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Figure 3: Absorbance of MTT treated spheroids following doxorubicin treatments at different times 
 
2. Nanoemulsion Testing 
Doxorubicin nanoemulsions were produced and placed into 5 wells of a clean 96 well plate, 
with 100 µL per well. Three wells were also filled with each of the following: 0.58% 
doxorubicin (the total concentration of doxorubicin in the nanoemulsion if all the 
doxorubicin used entered the nanoemulsions, or the theoretical loading) 0.058% 
doxorubicin, 5.8x10-3% doxorubicin, 5.8x10-4% doxorubicin, and 5.8x10-5% doxorubicin. 
100 µL was used here as well. Then each well received 100 µL of 4% methanol, which 
ruptured the nanoemulsions and allowed the doxorubicin to be released into solution. Since 
each sample had the same amount of methanol, a methanol background test was not 
necessary as any background reading would be the same for each sample. The fluorescence 
of the doxorubicin was read via a plate reader, and the concentration of doxorubicin in the 
nanoemulsions was estimated to be 14.6% of the maximum value, calculated from a 
polynomial curve that fits the data down to 5.8x10-5% doxorubicin within the linear range 
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efficiency was used in interpreting all nanoemulsion data in this paper as they were 
produced under the same conditions as all of the batches. .  
The size of the nanoemulsions was determined by diluting 12-day-old doxorubicin 
nanoemulsions in water and placing the solution in a NanoBrook ZetaPALS potential 
analyzer. The sample was scanned with a 658nm laser and the scattering within indicated 
the range of sizes for the nanoemulsions. The effective diameter was measured to be 703 
nm, which may have weakened penetration and thus effecasy but smaller nanoemulsions 
could be created using smaller filters.  
Additionally, the integrity lifespan of the nanoemulsions was tested by measuring the 
fluorescence of flat cells treated with FITC and AS1411/Cy5 FITC nanoemulsions which 
had been stored for up to 2 weeks after production. The FITC nanoemulsions contained 
FITC liquid while the AS1411/Cy5 FITC nanoemulsions contained FITC liquid and had 
AS1411/Cy5 bound to the membrane. The effectiveness of these nanoemulsions was 
determined by counting the cells that contained FITC or Cy5 after treatment and fixing to 
show how many cells would receive treatment with chemotherapeutic nanoemulsions. The 
results of this study are seen in Figure 6, with the controls being no treatment. The results 
show no difference between one day and one week as each is within one standard deviation 
of the other. After two weeks, significant leaking of the FITC was seen and fewer cells 
were marked when total cell association was tested after washing.  
Doxorubicin was used for the drug tests due to its chemotherapeutic properties. 
Doxorubicin has an IC50 Z-Score of 1.16291 on MDA-MB-231. A Z-Score of 2 or above 
indicates the cell line is resistant to the drug while a Z-Score of -2 or below indicates it is 
sensitive to the drug (Cancer RxGenes). The effect of doxorubicin on these cells has also 
been shown experimentally in our lab during a previous experiment. In Figure 6, the 







Figure 6: Percent Viability of MDA-MB-231 Cells Following Doxorubicin Treatment 
 
Figure 6: Weekly fluorescence test to determine nanoemulsion lifespan through treatment of flat cells. 
3. AS1411 Testing (Fluorescent) 
AS1411 and non-AS1411 fluorescent nanoemulsions were produced and applied to both 
single layer and spheroid cancer cells.  The cells were then be returned to incubation for 2 
days before being examined. Some samples were examined via flow cytometry. Other 
samples were sent through a plate reader for fluorescent reading. It was expected that the 
AS1411 nanoemulsions would result in more fluorescence within the cells as they bind to 
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noticeable, as AS1411 is used to cause the nanoemulsions to specifically target cancer 
tissue instead of healthy tissue. 
4. AS1411 Testing (Drug) 
AS1411 and non-AS1411 modified doxorubicin-loaded nanoemulsions were produced and 
applied to both single-layer cancer cells and spheroids. After two days of exposure in 
incubation, results were obtained. To measure cell viability, some sets were tested with an 
MTT assay after 2 days of growth. This two day waiting time was chosen based on the 
results of an experiment seen in Figure 5, as two days resulted in less variance than four 
days. It was expected that the AS1411 nanoemulsions would result in less cell viability, 
but this may be less noticeable for the reasons mentioned above as no non-cancer controls 
were used. As Figures 6 and 7 show below, there are inconsistent differences between the 
AS1411-targeted and untargeted nanoemulsions, with large standard deviations within 
some samples. An ANOVA for Figure 6 shows that both emulsion concentration and 
doxorubicin presence have statistically significant effects on the absorbance, but AS1411 
does not. AS1411 combined with emulsion concentration is shown to be statistically 
significant, but the results are clearly influenced by what are likely outliers, as the presence 
of AS1411 is shown to worsen the effect of some nanoemulsion concentrations. An 
ANOVA of Figure 7 could not be performed due to low R-Squared value (50.39%) found 
through Minitab. The background reading from blank nanoemulsions were not subtracted 
from the values as the presence of nanoemulsions weakened absorbance as seen between 






Figure 7: Percent Viability determined via plate reading for MTT treated (2 hour incubation) spheroids treated with doxorubicin 
nanoemulsions and ultrasound. 
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Figure10: The combined data from Figure 8 and 9. The normalized values of the absorbance from spheroids 
1. Ultrasound Testing (Fluorescent) 
It was expected that the ultrasound-treated spheroids would have absorbed more of the 
fluorescent material, resulting in a higher flow cytometry reading as the fluorescent 
molecules were delivered into the cell, and a lower pate reading as less MTT was converted 
due to greater cytotoxicity.  
2. Ultrasound Testing (Drug) 
Doxorubicin-loaded nanoemulsions were produced and applied to both single-layer and 
spheroid cancer cells. After 1 hour, half of the nanoemulsions were placed under ultrasound 
for a fixed period of time. Both ultrasound-treated and non-ultrasound treated emulsions 
were then placed in incubation for an additional 2 days before results were obtained. To 
measure cell viability an MTT assay was applied to some sets, the results of which are seen 
in Figure 8. Here, both nanoemulsions and liquid doxorubicin were tested with and without 
ultrasound. ANOVA could not be performed due to a low r-squared value of 38.82%. It 
was expected that the ultrasound-treated spheroids would be less viable compared to 
untreated spheroids. The liquid doxorubicin ANOVA for Figure 9 showed that the 
doxorubicin concentration had some effect on absorbance, but ultrasound did not, which 
was expected without nanoemulsions. Figures 9 and 10 confirms this by comparing 
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far from a normal distribution to perform an ANOVA. Figure 10 shows an unexpected 
increase in absorbance as doxorubicin concentration increases, but this may be due to 
doxorubicin being a similar color to the product of MTT assays, resulting in false positives. 
Since the goal of this experiment was to determine the effects of ultrasound and the samples 
are compared against those treated with the same amount of doxorubicin, this does not 
change the conclusion.  
 
 
Figure 9: Absorbance of MTT treated spheroids following doxorubicin treatment. Each emulsion sample contained 10µL of 
nanoemulsions, with the percentage indicating the amount that contained doxorubicin. Ultrasound occurred 30 minutes 
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Figure 10: Absorbance of MTT treated spheroids following liquid doxorubicin treatment 
 
3. Combined Testing (Fluorescent) 
AS1411 and non-AS1411 conjugated fluorescent nanoemulsions were produced and 
applied to both single-layer cancer cells and spheroids. After 1 hour, half of each type was 
placed under ultrasound for a fixed period of time. Then, all samples were returned to 
incubation for 2 days. For each sample type half of the wells were examined via flow 
cytometry while the other half were examined in a plate reader. It was expected that the 
AS1411/ultrasound cells would have the most fluorescence. The next most fluorescent 
would be ultrasound, followed by AS1411, as AS1411 is expected to less of a noticeable 
effect without noncancer cells to differentiate cancer from. Finally, the control is expected 
to have the least fluorescence.  We can see in Figure 11 below that the ultrasound-treated 
cells had consistently lower fluorescence intensity than the non-ultrasound treated cells and 
that AS1411 improved the cell counts. Figure 11 was normalized to the untargeted, non-
ultrasonicated samples as untreated samples were not used in this experiment. A similar 
experiment that shows how these treatments compare to a control can be seen in Figure 7. 
This can be explained as the ultrasonication creating holes in the cells allowing for the 
FITC to escape. Testing this on spheroids, as seen in Figure 12, shows less effect. The 
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intensity showed only the presence of Cy5/AS1411 and the combination of that presence 
with ultrasound to be significant. Specifically, the presence of Cy5/AS1411 increased the 
intensity while adding ultrasound to Cy5/AS1411 treated cells lowered it. The severe 
differences between Figures 11 and 12 are likely due to the use of flat cells in Figure 11 
and spheroids in Figure 12 or the immediate fixing of the cells in Figure 12’s experiments.  
 
Figure 11: Normalized values from Total Cell Association Flow Cytometry MACS Quantity Analyzer reading of FITC in flat cells 
after various treatments for 1 hour. (1=3341.7 cells) 
 
Figure 12: A normalized graph showing the cells counted via Total Cell Association Flow Cytometry MACS Quantity Analyzer 







































































4. Combined Testing (Drug) 
AS1411 and non-AS1411 conjugated doxorubicin nanoemulsions were produced and 
applied to both single-layer cells and spheroids. After 1 hour, half of each type were placed 
under ultrasound before each sample was returned to incubate for 2 days. Samples were 
treated under an MTT assay to measure viability. It was expected that the 
AS1411/ultrasound cells would have the most fluorescence. The next most fluorescent 
would be ultrasound, followed by AS1411. Finally, the control is expected to have the least 
fluorescence.   
Figure 13 shows the average absorbance from MTT assays of spheroids after nanoemulsion 
treatments. Some values have large standard deviations or are simply abnormally large. 
Unfortunately, no cause for these abnormalities have been found. Additional testing may 
find these to be outliers. Additionally, ANOVA could not be performed, as the residual 
tests were failed as seen in Figure 14. Specifically, the normal probability plot deviated 
from the center line drastically and the versus fit is drastically large on the right side.  
 
Figure 13: Absorbance of MTT in spheroids following nanoemulsion treatments. The number of blank nanoemulsions in each 
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 Cancer continues to be a major source of mortality worldwide. This paper has presented a 
plan to test two methods of localizing drug delivery in nanoemulsions. Combined, these methods 
may result in fewer side effects for current and future cancer patients. AS1411 surface modification 
has the potential to result in greater uptake into cancer cells specifically and greater accumulation 
around the tumor. Ultrasound-induced vaporization of nanoemulsions has the potential to increase 
penetration into the spheroid and increase drug uptake. Neither of these methods should affect 
healthy tissue, although the ultrasound is area specific and could injure healthy tissue adjacent to 








 The results of this study leave many areas for future research. While the combined effects 
of AS1411 and ultrasonication showed little increase compared to ultrasonication alone, this study 
was limited by the use of only cancerous cells. Future studies can experiment using cancerous 
spheroids and healthy tissue to see if AS1411 will encourage drug delivery to cancerous cells over 
healthy cells. Similarly, this experiment could be performed with an artificial circulatory system 
to see if the AS1411 will hold the nanoemulsions to the spheroids long enough for a high 
concentration to build up there so that only a short period of ultrasonication is necessary for 
treatment. If AS1411 is shown to contribute to the selectivity of the drug’s effects, in vivo testing 
in animals may be warranted. This study has yielded initial results on ultrasound’s ability to 
improve drug delivery in tumors in vivo and has revealed potential complications to avoid when 
testing the effects of AS1411 on nanoemulsions. Additional studies may include testing other 
chemicals to target cancer besides AS1411 and see how they influence uptake with ultrasound.  
There is some concern that the physical structures of spheroids prevent MTT from reaching 
cells in the center, skewing cell viability results. This was not anticipated in this paper and was not 
accounted for, which may have resulted in the effects of the drugs being stronger than recorded 
here. Future tests should involve a step disaggregating the spheroid without harming the cells prior 
to MTT application. Other studies have used the CellTiter-Glo Luminescent Assay to disaggregate 
the spheroids through lysis and determine the relative number of viable cells prior to lysing using 
the ATP that was in the cells. There was also concerns that doxorubicin could interfere with the 
absorbance of the crystals from the MTT assay. An absorbance test was performed, and while 
doxorubicin does show some absorbance at 570nm, it is very minor, with its peak absorbance being 
between 480 and 490 nm. Concerns were also raised that doxorubicin may be too easy of a drug 
to enter cells, thus negating some of the effects of the drug delivery mechanisms. Due to these 
concerns, it is suggested that future studies consider using other drugs to determine if these 
concerns are valid.  
Additional concerns are that the ultrasonication of nanoemulsions could induce metastasis 





spheroids. Future tests could verify the first concern by using MTT to test the viability of cells that 
break off from the spheroid during ultrasound treatment. Further testing with smaller 






Bates, Paula J, et al. “G-Quadruplex Oligonucleotide As1411 As a Cancer-Targeting Agent: 
Uses and Mechanisms.” Bba - General Subjects: Part B, vol. 1861, no. 5, 2017, pp. 1414–1428., 
doi:10.1016/j.bbagen.2016.12.015. 
“Cancer.” World Health Organization, World Health Organization, 
www.who.int/mediacentre/factsheets/fs297/en/. 
“Cancer Statistics.” National Cancer Institute, www.cancer.gov/about-
cancer/understanding/statistics. 
 “Chemotherapy Side Effects.” American Cancer Society, www.cancer.org/treatment/treatments-
and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html. 
“Genomics of Drug Sensitivity in Cancer.” CancerRxGenes, 
www.cancerrxgene.org/translation/CellLine/905960. 
Ivascu, A., Kubbies, M."Diversity of cell-mediated adhesions in breast cancer spheroids". 
International Journal of Oncology 31.6 (2007): 1403-1413. 
Luo Z, et al. “Precise Glioblastoma Targeting by As1411 Aptamer-Functionalized Poly (l-Γ-
Glutamylglutamine)-Paclitaxel Nanoconjugates.” Journal of Colloid and Interface Science, vol. 
490, 2017, pp. 783–796., doi:10.1016/j.jcis.2016.12.004. 
Muehlmann, Luis Alexandre, et al. “Aluminium-Phthalocyanine Chloride Nanoemulsions for 
Anticancer Photodynamic Therapy: Development and in Vitro Activity against Monolayers and 
Spheroids of Human Mammary Adenocarcinoma MCF-7 Cells.” Journal of Nanobiotechnology, 
vol. 13, no. 1, 2015, doi:10.1186/s12951-015-0095-3. 
Obrien, W.d., and J.f. Zachary. “Lung Damage Assessment from Exposure to Pulsed-Wave 
Ultrasound in the Rabbit, Mouse, and Pig.” IEEE Transactions on Ultrasonics, Ferroelectrics 





Zhou, Yufeng. “Ultrasound-Mediated Drug/Gene Delivery in Solid Tumor Treatment.” Journal 








Daniel Hodge received his Bachelor’s of Science in Bioengineering with honors from the University of 
Louisville in 2017. He was a pre-med student and completed the Guaranteed Entrance to Medical School 
program. While a student, he worked at Evolva as a research laboratory intern in Lexington, KY. He also 
worked as a medical scribe in Louisville emergency rooms through the company PhysAssist. He worked 
with Dr. Jill Steinbach-Rankins on researching the production and testing of nanofibers. The work with Dr. 
Steinbach-Rankins resulted in a publication. Daniel served as the president of the University of Louisville 
Biomedical Engineering Society. In his research with Dr. Steinbach-Rankins, he also learned how to culture 
mammalian cells. Currently, Daniel is completing his Masters of Engineering in Bioengineering at the 
University of Louisville under Dr. Jonathan Kopechek. Daniel has been accepted into the University of 
Louisville Medical School class of 2022 and will begin attending Fall of 2018.  
 
 
